

adenoviral genome, and wherein the pharmaceutical composition does not contain replication-competent adenoviruses.

37. (New) The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E1.

38. (New) The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E2A.

39. (New) The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E4.

40. (New) The composition of claim 36, wherein the adenoviral vector is deficient in two or more essential gene functions.

41. (New) The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E2A regions of the adenoviral genome.

42. (New) The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E4 regions of the adenoviral genome.

43. (New) The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E2A and E4 regions of the adenoviral genome.

44. (New) The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene function of each of three regions of the adenoviral genome.

45. (New) The composition of claim 44, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1, E2A, and E4 regions of the adenoviral genome.

46. (New) The composition of claim 36, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

47. (New) The composition of claim 37, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

48. (New) The composition of claim 38, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

49. (New) The composition of claim 39, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

50. (New) The composition of claim 40, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

51. (New) The composition of claim 41, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

52. (New) The composition of claim 42, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

53. (New) The composition of claim 43, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

54. (New) The composition of claim 44, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

55. (New) The composition of claim 45, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

REMARKS

The title has been amended to replace the existing title with a title that is more descriptive of the pending claims. The specification has been amended to indicate that the instant application is a continuation of a U.S. Patent Application No. 08/258,416. Claims 1-35 have been cancelled and claims 36-55 have been added. New claims 36-55 are supported by the claims as originally filed and by the specification in its entirety and, in particular, at page 11, lines 26-31, page 14, lines 8-17, and page 17, lines 6-15.

Please note that the new claims 36-55 are identical to issued claims 1-20 of U.S. Patent No. 5,994,106 (which issued from a continuation of the same parent patent application), except that the new claims are in the form of a "pharmaceutical composition" rather than a "stock." A copy of U.S. Patent No. 5,994,106 is enclosed herewith for the convenience of the Examiner.